Silverarc Capital Management’s Trevi Therapeutics TRVI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-678,095
Closed -$12.6M – 84
2026
Q2
$12.6M Buy
678,095
+166,968
+33% +$2.43M 1.31% 25
2026
Q1
$6.1M Sell
511,127
-30,113
-6% -$337K 0.62% 38
2025
Q4
$6.78M Sell
541,240
-47,549
-8% -$550K 0.94% 29
2025
Q3
$5.39M Buy
588,789
+49,202
+9% +$369K 0.73% 36
2025
Q2
$2.95M Buy
539,587
+9,587
+2% +$59.6K 0.54% 42
2025
Q1
$3.33M Sell
530,000
-204,234
-28% -$974K 0.68% 40
2024
Q4
$3.03M Buy
734,234
+251,659
+52% +$806K 0.66% 40
2024
Q3
$1.61M Sell
482,575
-361,660
-43% -$1.08M 0.36% 51
2024
Q2
$2.52M Hold
844,235
– – 0.59% 45
2024
Q1
$2.91M Sell
844,235
-19,648
-2% -$43.8K 0.81% 37
2023
Q4
$1.16M Sell
863,883
-63,532
-7% -$96.2K 0.34% 57
2023
Q3
$2.02M Buy
927,415
+41,491
+5% +$93.7K 0.61% 45
2023
Q2
$2.12M Hold
885,924
– – 0.66% 44
2023
Q1
$1.64M Buy
885,924
+118,293
+15% +$268K 0.68% 48
2022
Q4
$1.48M Sell
767,631
-171,634
-18% -$338K 0.42% 60
2022
Q3
$1.45M Buy
+939,265
New +$3.08M 0.49% 55

Other funds holding TRVI

Silverarc Capital Management's TRVI Position: Q3 2026 in Review

Silverarc Capital Management sold out of Trevi Therapeutics (TRVI) in Q3 2026, closing a stake of 678,095 shares — an estimated $12.6M sold.

Silverarc Capital Management first reported a position in TRVI in Q3 2022 and held it in 16 quarters. The position peaked at $12.6M in Q2 2026. 222 funds tracked by Wall St. Rank hold TRVI as of Q3 2026.

  • Silverarc Capital Management reported no remaining Trevi Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Silverarc Capital Management sold 678,095 Trevi Therapeutics shares in Q3 2026, an estimated $12.6M.
  • Silverarc Capital Management first reported a position in Trevi Therapeutics in Q3 2022 and held it in 16 quarters.
  • Silverarc Capital Management's Trevi Therapeutics position peaked at $12.6M in Q2 2026.
  • 222 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q3 2026.

Based on Silverarc Capital Management's 13F filing for Q3 2026, filed 12 Nov 2026.